Tina R Raine1, Anne Foster-Rosales, Ushma D Upadhyay, Cherrie B Boyer, Beth A Brown, Abby Sokoloff, Cynthia C Harper. 1. From the Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California; Division of Adolescent Medicine, Department of Pediatrics, University of California, San Francisco, San Francisco, California.
Abstract
OBJECTIVE: To assess contraceptive discontinuation, switching, factors associated with method discontinuation, and pregnancy among women initiating hormonal contraceptives. METHODS: This was a 12-month longitudinal cohort study of adolescent girls and women (n=1,387) aged 15 to 24 years attending public family planning clinics who did not desire pregnancy for at least 1 year and selected to initiate the patch, ring, depot medroxyprogesterone acetate, or pills. Participants completed follow-up assessments at 3, 6, and 12 months after baseline. Life table analysis was used to estimate survival rates for contraceptive continuation. Cox proportional hazards models were used to estimate factors associated with method discontinuation. RESULTS: The continuation rate (per 100 person-years) at 12 months was low for all methods; however, it was lowest for patch and depot medroxyprogesterone acetate initiators, 10.9 and 12.1 per 100 person years, respectively (P≤.003); continuation among ring initiators was comparable to pill initiators, 29.4 and 32.7 per 100 person-years, respectively (P=.06). Discontinuation was independently associated with method initiated and younger age. The only factors associated with lower risk of discontinuation were greater intent to use the method and being in school or working. The pregnancy rate (per 100 person-years) was highest for patch and ring initiators (30.1 and 30.5) and comparable for pill and depot medroxyprogesterone acetate initiators (16.5 and 16.1; P<.001). CONCLUSION: The patch and the ring may not be better options than the pill or depot medroxyprogesterone acetate for women at high risk for unintended pregnancy. This study highlights the need for counseling interventions to improve contraceptive continuation, education about longer-acting methods, and developing new contraceptives that women may be more likely to continue. LEVEL OF EVIDENCE: II.
OBJECTIVE: To assess contraceptive discontinuation, switching, factors associated with method discontinuation, and pregnancy among women initiating hormonal contraceptives. METHODS: This was a 12-month longitudinal cohort study of adolescent girls and women (n=1,387) aged 15 to 24 years attending public family planning clinics who did not desire pregnancy for at least 1 year and selected to initiate the patch, ring, depot medroxyprogesterone acetate, or pills. Participants completed follow-up assessments at 3, 6, and 12 months after baseline. Life table analysis was used to estimate survival rates for contraceptive continuation. Cox proportional hazards models were used to estimate factors associated with method discontinuation. RESULTS: The continuation rate (per 100 person-years) at 12 months was low for all methods; however, it was lowest for patch and depot medroxyprogesterone acetate initiators, 10.9 and 12.1 per 100 person years, respectively (P≤.003); continuation among ring initiators was comparable to pill initiators, 29.4 and 32.7 per 100 person-years, respectively (P=.06). Discontinuation was independently associated with method initiated and younger age. The only factors associated with lower risk of discontinuation were greater intent to use the method and being in school or working. The pregnancy rate (per 100 person-years) was highest for patch and ring initiators (30.1 and 30.5) and comparable for pill and depot medroxyprogesterone acetate initiators (16.5 and 16.1; P<.001). CONCLUSION: The patch and the ring may not be better options than the pill or depot medroxyprogesterone acetate for women at high risk for unintended pregnancy. This study highlights the need for counseling interventions to improve contraceptive continuation, education about longer-acting methods, and developing new contraceptives that women may be more likely to continue. LEVEL OF EVIDENCE: II.
Authors: David F Archer; Alison Bigrigg; Geoffrey H Smallwood; Gary A Shangold; George W Creasy; Alan C Fisher Journal: Fertil Steril Date: 2002-02 Impact factor: 7.329
Authors: Robert M Groves; Grant Benson; William D Mosher; Jennifer Rosenbaum; Peter Granda; William Axinn; James Lepkowski; Anjani Chandra Journal: Vital Health Stat 1 Date: 2005-08
Authors: Mitchell D Creinin; Leslie A Meyn; Lynn Borgatta; Kurt Barnhart; Jeff Jensen; Anne E Burke; Carolyn Westhoff; Melissa Gilliam; Caryn Dutton; Susan A Ballagh Journal: Obstet Gynecol Date: 2008-02 Impact factor: 7.661
Authors: Tina R Raine; Jennifer C Gard; Cherrie B Boyer; Sadia Haider; Beth A Brown; F Antonio Ramirez Hernandez; Cynthia C Harper Journal: Cult Health Sex Date: 2010-05
Authors: Somsook Santibenchakul; Mary Tschann; Alyssa Dee P Carlson; Eric L Hurwitz; Jennifer Salcedo Journal: J Midwifery Womens Health Date: 2018-12-20 Impact factor: 2.388
Authors: Cynthia C Harper; Laura Stratton; Tina R Raine; Kirsten Thompson; Jillian T Henderson; Maya Blum; Debbie Postlethwaite; J Joseph Speidel Journal: Prev Med Date: 2013-10-12 Impact factor: 4.018
Authors: Britt Lunde; Lisa Littman; Samantha Stimmel; Rima Rana; Adam Jacobs; Carol R Horowitz Journal: J Pediatr Adolesc Gynecol Date: 2017-01-06 Impact factor: 1.814
Authors: Cynthia C Harper; Jillian T Henderson; Tina R Raine; Suzan Goodman; Philip D Darney; Kirsten M Thompson; Christine Dehlendorf; J Joseph Speidel Journal: Fam Med Date: 2012-10 Impact factor: 1.756